Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | DHODH | Q02127 | 2/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | FBP1 | P09467 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
| ▸ | FPR1 | P21462 | 1/20 | 0.39 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9627436 | 0.77 | ABCB11 (0.52) | BACE1MAPTTDP1LMNAGAA | |
| SCHEMBL9934162 | 0.74 | NR4A2 (0.46) | MAPTTDP1FFAR1TRPV1FPR1 | |
| SCHEMBL9642256 | 0.74 | ABCB11 (0.61) | BACE1MAPTTDP1LMNAGAA | |
| SCHEMBL8469479 | 0.72 | LMNA (0.65) | BACE1MAPTTDP1LMNAGAA | |
| SCHEMBL9898347 | 0.71 | DHODH (0.50) | BACE1LMNAGAADHODHKDM4E | |
| SCHEMBL26009136 | 0.70 | LMNA (0.59) | BACE1MAPTTDP1LMNAGAA | |
| Acetic Acid SCHEMBL28960935 | 0.70 | HDAC4 (0.61) | LMNAFFAR1TRPV1 | |
| SCHEMBL9642501 | 0.69 | PDE4A (0.53) | BACE1MAPTTDP1LMNAGAA | |
| SCHEMBL8469858 | 0.69 | LMNA (0.60) | BACE1MAPTTDP1LMNAGAA | |
| SCHEMBL5849176 | 0.69 | RXRA (0.56) | FBP1TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2651914-B1 | PHOTOCHROMIC COMPOUNDS AND COMPOSITIONS | TRANSITIONS OPTICAL INC (US) | 2015-05-13 | — | — | EP | disclosed |
| US-8920928-B2 | Photochromic compounds and compositions | TRANSITIONS OPTICAL, INC. (US) | 2014-12-30 | — | — | US | disclosed |
| EP-2651914-A1 | PHOTOCHROMIC COMPOUNDS AND COMPOSITIONS | Transitions Optical, Inc. (US) | 2013-10-23 | — | — | EP | disclosed |
| WO-2012082999-A1 | PHOTOCHROMIC COMPOUNDS AND COMPOSITIONS | TRANSITIONS OPTICAL, INC. (US) | 2012-06-21 | — | — | WO | disclosed |
| US-20120156508-A1 | PHOTOCHROMIC COMPOUNDS AND COMPOSITIONS | TRANSITIONS OPTICAL, INC. (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120156508-A1 | PHOTOCHROMIC COMPOUNDS AND COMPOSITIONS | CRY2, CRY1, IPO4 | BACE1 3160/4885MAPT 562/4885TDP1 892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.